Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Revenue (2021 - 2025)

Mirum Pharmaceuticals has reported Revenue over the past 5 years, most recently at $148.9 million for Q4 2025.

  • Quarterly results put Revenue at $148.9 million for Q4 2025, up 49.81% from a year ago — trailing twelve months through Dec 2025 was $521.3 million (up 54.74% YoY), and the annual figure for FY2025 was $521.3 million, up 54.74%.
  • Revenue for Q4 2025 was $148.9 million at Mirum Pharmaceuticals, up from $133.0 million in the prior quarter.
  • Over the last five years, Revenue for MIRM hit a ceiling of $148.9 million in Q4 2025 and a floor of $3.1 million in Q4 2021.
  • Median Revenue over the past 5 years was $47.7 million (2023), compared with a mean of $60.0 million.
  • Biggest five-year swings in Revenue: soared 789.29% in 2022 and later skyrocketed 42.93% in 2024.
  • Mirum Pharmaceuticals' Revenue stood at $3.1 million in 2021, then skyrocketed by 789.29% to $27.9 million in 2022, then skyrocketed by 149.24% to $69.6 million in 2023, then skyrocketed by 42.93% to $99.4 million in 2024, then soared by 49.81% to $148.9 million in 2025.
  • The last three reported values for Revenue were $148.9 million (Q4 2025), $133.0 million (Q3 2025), and $127.8 million (Q2 2025) per Business Quant data.